188 related articles for article (PubMed ID: 36593395)
21. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
23. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells.
Notter M; Ludwig WD; Bremer S; Thiel E
Blood; 1993 Nov; 82(10):3113-24. PubMed ID: 7693036
[TBL] [Abstract][Full Text] [Related]
24. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells.
Fanger NA; Voigtlaender D; Liu C; Swink S; Wardwell K; Fisher J; Graziano RF; Pfefferkorn LC; Guyre PM
J Immunol; 1997 Apr; 158(7):3090-8. PubMed ID: 9120261
[TBL] [Abstract][Full Text] [Related]
25. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice.
Keler T; Guyre PM; Vitale LA; Sundarapandiyan K; van De Winkel JG; Deo YM; Graziano RF
J Immunol; 2000 Dec; 165(12):6738-42. PubMed ID: 11120792
[TBL] [Abstract][Full Text] [Related]
26. FcγR Binding and ADCC Activity of Human IgG Allotypes.
de Taeye SW; Bentlage AEH; Mebius MM; Meesters JI; Lissenberg-Thunnissen S; Falck D; Sénard T; Salehi N; Wuhrer M; Schuurman J; Labrijn AF; Rispens T; Vidarsson G
Front Immunol; 2020; 11():740. PubMed ID: 32435243
[TBL] [Abstract][Full Text] [Related]
27. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
[TBL] [Abstract][Full Text] [Related]
28. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
29. Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes.
Namboodiri AM; Pandey JP
Clin Exp Immunol; 2011 Dec; 166(3):361-5. PubMed ID: 22059994
[TBL] [Abstract][Full Text] [Related]
30. Functions of the various IgG Fc receptors in mediating killing of Toxoplasma gondii.
Erbe DV; Pfefferkorn ER; Fanger MW
J Immunol; 1991 May; 146(9):3145-51. PubMed ID: 1826707
[TBL] [Abstract][Full Text] [Related]
31. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
32. Comparative functional characterization of canine IgG subclasses.
Bergeron LM; McCandless EE; Dunham S; Dunkle B; Zhu Y; Shelly J; Lightle S; Gonzales A; Bainbridge G
Vet Immunol Immunopathol; 2014 Jan; 157(1-2):31-41. PubMed ID: 24268690
[TBL] [Abstract][Full Text] [Related]
33. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.
Treffers LW; Zhao XW; van der Heijden J; Nagelkerke SQ; van Rees DJ; Gonzalez P; Geissler J; Verkuijlen P; van Houdt M; de Boer M; Kuijpers TW; van den Berg TK; Matlung HL
Eur J Immunol; 2018 Feb; 48(2):344-354. PubMed ID: 28952147
[TBL] [Abstract][Full Text] [Related]
34. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS
Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830
[TBL] [Abstract][Full Text] [Related]
35. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells.
Sung AP; Tang JJ; Guglielmo MJ; Redelman D; Smith-Gagen J; Bateman L; Hudig D
J Immunol Methods; 2018 Jan; 452():63-72. PubMed ID: 29113954
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
Caron PC; Lai LT; Scheinberg DA
Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
[TBL] [Abstract][Full Text] [Related]
37. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
38. A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics.
Heijnen IA; Van de Winkel JG
J Hematother; 1995 Oct; 4(5):351-6. PubMed ID: 8581368
[TBL] [Abstract][Full Text] [Related]
39. An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH.
Liu Y; Lee AG; Nguyen AW; Maynard JA
J Biol Chem; 2022 Apr; 298(4):101798. PubMed ID: 35248534
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
